Anglo-Jordanian Hikma Pharmaceuticals plc (OTCPK:HKMPY) has had some curious ups and downs over the past two years. The company contemplated selling its injectables business (and got bids) only to decide to keep it, and the company's U.S. oral generics business was hurt by a warning letter in 2012 only to see a shortage of doxycycline in the U.S. lead to significant revenue and profit growth.
Hikma is going to be hard-pressed to maintain that momentum in doxycycline, but this remains a business with some strong growth potential. Not only is Hikma looking to leverage its position as the leading local manufacturer of branded generics for the Middle East and North African markets, but the company has begun to...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|